Merck boosts late-phase cancer pipeline with $1.1B Peloton buy


Merck struck a deal to buy Peloton Therapeutics for $1.1B upfront days before the biotech was due to list on Nasdaq. This deal will give Merck control of an experimental oral HIF-2α inhibitor that could challenge Keytruda for the metastatic renal cell carcinoma market.


Peloton was due to go public this week and raise $150M or more, but a late offer from Merck has persuaded the biotech to switch lanes. Merck could pay $1.2B in milestones on top of the $1.1B cash upfront.


Read the full article at…


Comments are closed.

More in Ashton Tweed Connection, News & Trends
Biotech’s top 10 money raisers of 2018

2017 was a big year for biotech venture capital, and 2018 managed to top it. Last year, private biotech companies...